Statements

CSRxP: PASSAGE OF CORNYN-BLUMENTHAL AND Q1/Q2 REFORMS WOULD BE POSITIVE STEPS TOWARD HOLDING BIG PHARMA ACCOUNTABLE FOR PATENT ABUSE

Dec 17, 2024

Bipartisan, Market-Based Solutions Would Crack Down on Big Pharma’s Patent Read More

CSRxP: USPTO WITHDRAWAL OF PATENT THICKET RULE ADDS TO URGENCY FOR CONGRESS TO PASS CORNYN-BLUMENTHAL

Dec 4, 2024

Lawmakers Must Act to Hold Big Pharma Accountable for Egregious Patent Abuse Read More

CSRxP STATEMENT ON SENATE JUDICIARY MARKUP OF THE PREVAIL ACT

Nov 21, 2024

Congress Should Not Further Consider Misguided Proposal That Would Enable More Read More

CSRxP APPLAUDS REINTRODUCTION OF REMEDY ACT IN U.S. SENATE 

Jul 31, 2024

Bipartisan, Market-Based Solution Would Help Crack Down on Anti-Competitive Read More

CSRXP: BIG PHARMA IS AT IT AGAIN, HIKES PRICES ON NEARLY 200 PRESCRIPTION DRUGS AS PART OF MID-YEAR INCREASES

Jul 15, 2024

Brand Name Drug Giants’ Average Price Increases for June-July Outpace Rate Read More

CSRXP APPLAUDS U.S. SENATE PASSAGE OF BIPARTISAN, MARKET-BASED SOLUTION TO CRACK DOWN ON BIG PHARMA’S PATENT THICKETS

Jul 11, 2024

Legislation Would Hold Big Pharma Accountable for Anti-Competitive Tactics Read More

NEW GOODRX REPORT UNDERSCORES NEED FOR CONGRESS TO HOLD BIG PHARMA ACCOUNTABLE

Jul 2, 2024

Latest Data Finds List Prices of Prescription Drug Prices Have Increased Read More